我的最终目标是将从PubMed接收的元数据加载到pyspark数据帧中。
到目前为止，我已经成功地使用Shell脚本从PubMed数据库下载了我想要的数据。
下载的数据为asn1格式。这是数据输入的示例：
Pubmed-entry ::= {
pmid 31782536,
medent {
em std {
year 2019,
month 11,
day 30,
hour 6,
minute 0
},
cit {
title {
name "Impact of CYP2C19 genotype and drug interactions on voriconazole
plasma concentrations: a spain pharmacogenetic-pharmacokinetic prospective
multicenter study."
},
authors {
names std {
{
name ml "Blanco Dorado S",
affil str "Pharmacy Department, University Clinical Hospital
Santiago de Compostela (CHUS). Santiago de Compostela, Spain.; Clinical
Pharmacology Group, University Clinical Hospital, Health Research Institute
of Santiago de Compostela (IDIS). Santiago de Compostela, Spain.; Department
of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy,
University of Santiago de Compostela (USC). Santiago de Compostela, Spain."
},
{
name ml "Maronas O",
affil str "Genomic Medicine Group, Centro Nacional de Genotipado
(CEGEN-PRB3), CIBERER, CIMUS, University of Santiago de Compostela (USC),
Santiago de Compostela, Spain."
},
{
name ml "Latorre-Pellicer A",
affil str "Genomic Medicine Group, Centro Nacional de Genotipado
(CEGEN-PRB3), CIBERER, CIMUS, University of Santiago de Compostela (USC),
Santiago de Compostela, Spain."
},
{
name ml "Rodriguez Jato T",
affil str "Pharmacy Department, University Clinical Hospital
Santiago de Compostela (CHUS). Santiago de Compostela, Spain."
},
{
name ml "Lopez-Vizcaino A",
affil str "Pharmacy Department, University Hospital Lucus Augusti
(HULA). Lugo, Spain."
},
{
name ml "Gomez Marquez A",
affil str "Pharmacy Department, University Hospital Ourense
(CHUO). Ourense, Spain."
},
{
name ml "Bardan Garcia B",
affil str "Pharmacy Department, University Hospital Ferrol (CHUF).
A Coruna, Spain."
},
{
name ml "Belles Medall D",
affil str "Pharmacy Department, General University Hospital
Castellon (GVA). Castellon, Spain."
},
{
name ml "Barbeito Castineiras G",
affil str "Microbiology Department, University Clinical Hospital
Santiago de Compostela (CHUS). Santiago de Compostela, Spain."
},
{
name ml "Perez Del Molino Bernal ML",
affil str "Microbiology Department, University Clinical Hospital
Santiago de Compostela (CHUS). Santiago de Compostela, Spain."
},
{
name ml "Campos-Toimil M",
affil str "Department of Pharmacology, Pharmacy and Pharmaceutical
Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC).
Santiago de Compostela, Spain."
},
{
name ml "Otero Espinar F",
affil str "Department of Pharmacology, Pharmacy and Pharmaceutical
Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC).
Santiago de Compostela, Spain."
},
{
name ml "Blanco Hortas A",
affil str "Epidemiology Unit. Fundacion Instituto de Investigacion
Sanitaria de Santiago de Compostela (FIDIS), University Hospital Lucus
Augusti (HULA), Spain."
},
{
name ml "Duran Pineiro G",
affil str "Clinical Pharmacology Group, University Clinical
Hospital, Health Research Institute of Santiago de Compostela (IDIS).
Santiago de Compostela, Spain."
},
{
name ml "Zarra Ferro I",
affil str "Pharmacy Department, University Clinical Hospital
Santiago de Compostela (CHUS). Santiago de Compostela, Spain.; Clinical
Pharmacology Group, University Clinical Hospital, Health Research Institute
of Santiago de Compostela (IDIS). Santiago de Compostela, Spain."
},
{
name ml "Carracedo A",
affil str "Genomic Medicine Group, Centro Nacional de Genotipado
(CEGEN-PRB3), CIBERER, CIMUS, University of Santiago de Compostela (USC),
Santiago de Compostela, Spain.; Galician Foundation of Genomic Medicine,
Health Research Institute of Santiago de Compostela (IDIS), SERGAS, Santiago
de Compostela, Spain."
},
{
name ml "Lamas MJ",
affil str "Clinical Pharmacology Group, University Clinical
Hospital, Health Research Institute of Santiago de Compostela (IDIS).
Santiago de Compostela, Spain."
},
{
name ml "Fernandez-Ferreiro A",
affil str "Pharmacy Department, University Clinical Hospital
Santiago de Compostela (CHUS). Santiago de Compostela, Spain.; Clinical
Pharmacology Group, University Clinical Hospital, Health Research Institute
of Santiago de Compostela (IDIS). Santiago de Compostela, Spain.; Department
of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy,
University of Santiago de Compostela (USC). Santiago de Compostela, Spain."
}
}
},
from journal {
title {
iso-jta "Pharmacotherapy",
ml-jta "Pharmacotherapy",
issn "1875-9114",
name "Pharmacotherapy"
},
imp {
date std {
year 2019,
month 11,
day 29
},
language "eng",
pubstatus aheadofprint,
history {
{
pubstatus other,
date std {
year 2019,
month 11,
day 30,
hour 6,
minute 0
}
},
{
pubstatus pubmed,
date std {
year 2019,
month 11,
day 30,
hour 6,
minute 0
}
},
{
pubstatus medline,
date std {
year 2019,
month 11,
day 30,
hour 6,
minute 0
}
}
}
}
},
ids {
pubmed 31782536,
doi "10.1002/phar.2351",
other {
db "ELocationID doi",
tag str "10.1002/phar.2351"
}
}
},
abstract "BACKGROUND: Voriconazole, a first-line agent for the treatment
of invasive fungal infections, is mainly metabolized by cytochrome P450 (CYP)
2C19. A significant portion of patients fail to achieve therapeutic
voriconazole trough concentrations, with a consequently increased risk of
therapeutic failure. OBJECTIVE: To show the association between
subtherapeutic voriconazole concentrations and factors affecting voriconazole
pharmacokinetics: CYP2C19 genotype and drug-drug interactions. METHODS:
Adults receiving voriconazole for antifungal treatment or prophylaxis were
included in a multicenter prospective study conducted in Spain. The
prevalence of subtherapeutic voriconazole troughs were analyzed in the rapid
metabolizer and ultra-rapid metabolizer patients (RMs and UMs, respectively),
and compared with the rest of the patients. The relationship between
voriconazole concentration, CYP2C19 phenotype, adverse events (AEs), and
drug-drug interactions was also assessed. RESULTS: In this study 78 patients
were included with a wide variability in voriconazole plasma levels with only
44.8% of patients attaining trough concentrations within the therapeutic
range of 1 and 5.5 microg/ml. The allele frequency of *17 variant was found
to be 29.5%. Compared with patients with other phenotypes, RMs and UMs had a
lower voriconazole plasma concentration (RM/UM: 1.85+/-0.24 microg/ml versus
other phenotypes: 2.36+/-0.26 microg/ml, ). Adverse events were more common
in patients with higher voriconazole concentrations (p<0.05). No association
between voriconazole trough concentration and other factors (age, weight,
route of administration, and concomitant administration of enzyme inducer,
enzyme inhibitor, glucocorticoids, or proton pump inhibitors) was found.
CONCLUSION: These results suggest the potential clinical utility of using
CYP2C19 genotype-guided voriconazole dosing to achieve concentrations in the
therapeutic range in the early course of therapy. Larger studies are needed
to confirm the impact of pharmacogenetics on voriconazole pharmacokinetics.",
pmid 31782536,
pub-type {
"Journal Article"
},
status publisher
}
}
这就是我被困住的地方。我不知道如何从asn1中提取信息并将其放入pyspark数据帧中。有人可以建议这样做的方法吗？
最佳答案
以上数据肯定是“ ASN.1格式”。此格式称为ASN.1值表示法，用于以文本形式表示ASN.1值。 （这种格式早于JSON编码规则的标准化。如今，人们可以将JSON用于相同的目的，与ASN.1值表示法相比，JSON的处理方式有所不同）。
正如YaFred自己指出的那样，YaFred上面发布的ASN.1模式包含一些错误。您自己发布的符号似乎还包含一些错误。我查看了NCBI的整个ASN.1文件集，发现它们包含几个错误。因此，除非将其固定，否则无法使用符合标准的ASN.1工具（例如ASN.1游乐场）进行处理。其中的一些错误易于修复，但是要修复其他错误，则需要了解这些文件的作者的意图。这种状况可能是由于NCBI项目使用了自己的ASN.1工具包，该工具包可能以某种非标准的方式使用了ASN.1。
我想在NCBI工具箱中应该有一些方法可以让您解码上述值表示法，因此，如果您是我，我将研究该工具箱。我无法给您更好的建议，因为我不知道NCBI工具包。
关于python - 如何从asn1数据文件中提取数据并将其加载到数据帧中？，我们在Stack Overflow上找到一个类似的问题：https://stackoverflow.com/questions/59219279/